CoChat

Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes

Vuppalanchi, Raj, Chalasani, Naga, Teal, Evegenia · 2005 · The American Journal of the Medical Sciences

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background It is recommended that lovastatin be avoided in patients with unexplained elevation in transaminase levels. However, there are no studies that evaluated the risk of lovastatin hepatotoxicity in subjects with elevated liver enzymes. Our study tested the hypothesis that patients with elevated liver enzymes are not at higher risk for hepatotoxicity from lovastatin.Methods Our study consisted of the following three cohorts of patients seen between December 1987 and December 1998: cohort 1: 135 patients with elevated baseline enzymes (aspartate transaminase [AST] >40 IU/L or alanine transaminase [ALT] >35 IU/L) who received lovastatin; cohort 2: 620 patients without elevated liver enzymes who received lovastatin; and cohort 3: 2644 patients with elevated liver enzymes but not prescribed lovastatin. Elevations in liver biochemistries over a 12-month period after lovastatin was prescribed were categorized into mild-moderate or severe elevations and into "Hy's Rule" based on published criteria.Results The incidence of mild-moderate elevations and severe elevations in liver biochemistries in cohort 1 were 6.6% and 0%, respectively. Compared with cohort 2, individuals in cohort 1 had higher incidence of mild-moderate elevations (6.6% versus 3%; P = 0.03) but not severe elevations (0% versus 0.3%; P = 0.9). Compared with cohort 3, patients in cohort 1 had similar mild-moderate elevations (6.6% versus 11%; P = 0.2) but lower severe elevations (0% versus 5.5%; P < 0.01). No one in cohorts 1 or 2 developed elevations meeting Hy's Rule, whereas 3.5% of the patients in cohort 3 exhibited such elevations (P < 0.05 versus cohort 1 or cohort 2).Conclusions Significant hepatotoxicity from lovastatin was very infrequent in this study, and individuals with elevated baseline liver enzyme levels did not have higher frequency of lovastatin hepatotoxicity than those with normal liver enzyme levels.

Overview

Integrity signals

Registry

Crossref · 10.1097/00000441-200502000-00002

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 139

Metadata

Authors
Vuppalanchi, R., Chalasani, N., & Teal, E.
Affiliations
  • Indiana University Indianapolis (US)
  • Regenstrief Institute (US)
Corresponding author
Chalasani, Naga
Venue
The American Journal of the Medical Sciences
Publisher
Elsevier BV
Published
2005-02
Volume
329
Issue
2
Pages
62-65
ISSN
0002-9629 (ISSN-L)
OpenAlex
W2073776492
Cited by
133
References
30
Citations by year
2025: 2 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 3 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 15 · 2012: 10
FWCI
7.63
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The American Journal of the Medical Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
lovastatin, drug-induced liver injury, elevated liver enzymes, aspartate aminotransferase, alanine aminotransferase, statins, drug safety, adverse drug reactions
MeSH terms
Adult, Aged, Female, Humans, Liver, Liver Function Tests, Lovastatin, Male, Middle Aged, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. https://app.cochat.ai/papers/10.1097/00000441-200502000-00002
The paper
Vuppalanchi, R., Chalasani, N., & Teal, E. (2005). Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes. The American Journal of the Medical Sciences. https://doi.org/10.1097/00000441-200502000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.